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A novel class of aminopyrrolidinyl phosphonates was synthesized in 74% - 
80% isolated yield by the addition of three-fold excess of primary amines to 
diethyl 4-chloro-1-butynylphosphonates. The reaction was carried out at 
room temperature and in the absence of solvent or catalyst to give solely 
compounds which showed predicted biological activity based on PASS pro-
gram. Some of the synthesized derivatives of antibiotics exhibit properties for 
the treatment of stroke, the treatment of acute neurological disorders, and 
can also be acetyl esterase inhibitors. 
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1. Introduction 
Natural antibiotics are produced by many microorganisms and are of great in-
terest in medicine and pharmacology [1] [2] [3] [4]. It is well known that some 
antibiotics, such as K-26, SF-2513, FR-33289, and SF-2312 contain a C-P (car-
bon-phosphorus) bond that belongs to the category of phosphonates [5] [6] [7] 
[8]. The targeted synthesis of phosphonates for pharmacological utility is also 
fairly well described in several reviews [9] [10] [11] [12] [13].  
For instance, a pyrrolidinyl phosphonates class (known as antibiotic SF-2312) 
How to cite this paper: Al Quntar, A.A.A., 
Dweik, H., Jabareen, A., Gloriozova, T.A. 
and Dembitsky, V.M. (2020) An Amino-
pyrrolidinyl Phosphonates—A New Class 
of Antibiotics: Facile Synthesis and Pre-
dicted Biological Activity. International 
Journal of Organic Chemistry, 10, *-*.  
https://doi.org/10.4236/***.2020.***** 
 
Received: **** **, *** 
Accepted: **** **, *** 
Published: **** **, *** 
 
Copyright © 2020 by author(s) and  
Scientific Research Publishing Inc. 
This work is licensed under the Creative 
Commons Attribution International  
License (CC BY 4.0). 
http://creativecommons.org/licenses/by/4.0/   
  
Open Access
A. A. A. Al Quntar et al. 
 
 
DOI: 10.4236/***.2020.***** 2 International Journal of Organic Chemistry 
 
is a natural antibiotic which is produced by the actinomycete Micromonospora 
sp. It has not only showed activity as an enolase inhibitor but also found to be 
one of the most potent natural inhibitors of glycolysis which in turn inhibit cell 
proliferation [14] [15] [16] [17] [18]. Later, the synthesis of this antibiotic and its 
analogues has been described by various researchers [19] [20] [21].  
In the same context, pharmacologists always agree that the biological activity 
of both natural and synthetic compounds is related to the chemical structure 
[22]. Therefore, there are a large number of available computer programs that 
can evaluate the probability of an organic compound activity to be a drug [23] 
[24]. For instance, PASS computer program contains a library with information 
of about 1 million chemical compounds and more than 10,000 biological activi-
ties [25]. An algorithm for the practical use of PASS has been described in detail 
in several publications [26] [27] [28].  
Previously, few pyrrolidinylphosphonates and pyrrolidinylphosphonic acids 
(1-12, Figure 1) were synthesized for the purpose of testing their biological ac-
tivity. Generally, they were obtained either from readily available pyrrolidine 
ring or by multistep cyclization reactions. But there is no one general direct me-
thod to produce them and a brief summary for their synthesis is described be-
low: 
Initially, the antibiotic SF-2312 (1) and its analogue (3) were synthesized by a 
multistep reaction sequence in which ethyl diethoxyphosphorylacetate was con-
verted to N-benzyloxy-2-(diethoxyphosphoryl)-pent-4-enamide followed by 
oxidative cleavage and hydrolysis [21]. Later, studies showed that their antibiotic 
activity is due to the inhibition of a glycolytic enzyme called enolase [14] [15] 
[16]. The reaction of pentanedial with acetamide and acetyl chloride in the 
presence of phosphorylating agent afforded the pyrrolidinyldiphosphonic acid 
(2) [29]. The combination of the Kabachnik–Fields reaction with a subsequent 
ring closure of 5-chloro-2-pentanone with ammonia and diethyl phosphonate 
produced (4) [30].  
The pyrrolidinylphosphonates (5-6) were prepared from readily available 
2-methylpyrroline and diethyl phosphite [31]. The SF-2312 (1) antibiotic analo-
gues (7-10) were obtained using 1-benzyloxy-3-bromopyrrolidin-2,5-dione 
through Michaelis-Arbusov reaction with trialkyl phosphites followed by alkyla-
tion. However, their biological activity was not determined [19] [20].  
Asymmetric synthesis of β-amidophosphonate (11) was achieved by Di-
els–Alder reaction between the vinylphosphonate and chiral aminodiene [32]. 
Finally, three-component decarboxylative coupling of proline with aldehydes 
and dialkyl phosphite was used to afford the corresponding pyrrolidinylphos-
phonates (12) [33].  
2. Results and Discussion 
We recently reported the synthesis of N-substituted  
pyrrolidinyl-methylphosphonate (14) by addition of amines to (Z)-diethyl 
(5-chloropent-1-en-1-yl)phosphonate 13 (Scheme 1) [34].  
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Figure 1. Pyrrolidinyl phosphonates 1-12. 
 
 
Scheme 1. Formation of pyrrolidines N-substituted 
pyrrolidinyl-methylphosphonate 14. 
 
In addition, we investigated the reaction of 4-chloro-1-butentynylphosphonate 
15 with an equivalent number of amines which gave  
2-amino-cyclobutenylphosphonates [35]. Interestingly, a different novel class of 
compounds (17a-h) was obtained by tuning of the reaction conditions. 
Being encouraged by these results, we determined to study amine addition on 
a shorter chain alkynylphosphonate that has not been explored before. Accor-
dingly, we prepared 4-chloro-1-butentynylphosphonate 15 in our lab by substi-
tuting the hydroxy group in but-3-yne-1-ol using thionyl chloride under reflux. 
After isolation of the product by distillation, it was lithiated using n-BuLi, and 
was reacted with chlorophosphonates. 
Herein, we report a very facile method for the synthesis of novel aminopyrro-
lidinyl phosphonates (17a-h) and their predicted biological activity using the 
PASS program.  
Thus, when three equivalents of i-propylamine were added to (15), the pyrroli-
dine structure diethyl (1-isopropyl-3-(isopropylamino)pyrrolidin-2-yl)phosphonate 
(17a) was gained in 80% yield (Scheme 2). Similarly, products (17b-h) were 
produced in (74% - 79%) isolated yield by treatment of 15 with a different pri-
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Scheme 2. Formation of pyrrolidinylphosphonate 17a. 
 
The reaction was carried out at 25˚C for 12 h. and the products 17 were iso-
lated by silica gel column chromatography in good yields (74% - 80%) and were 
characterized by NMR, GC/MS, and by elemental analysis. The multiplets in the 
regions ~ (1.3 - 2. 0 ppm), ~ (2.1 - 3.0 ppm) in the 1H NMR spectrum, precisely 
the doublet of doublet in the region ~ 2 ppm that corresponds to the hydrogen 
on C1 split by phosphorus and the hydrogen on C2 which resonated as a mul-
tiplet at ~ 3 ppm, together with the carbons in the regions ~ (30, 32, 45, 55 ppm) 
in the 13C NMR spectra are indicative of the pyrrolidine ring. Besides, the 31P 
NMR that resonated chemical shifts at ~ 31 ppm, the GC/MS and the elemental 
analysis are all evidence of structure 17. These results were also supported by 
2-D Cosy and 1H-13C HSQCSI NMR of 17d in which a high correlation was ob-
served.  
As described above, pyrrolidines 1-12 are of predicted biologically active 
compounds despite the multistep procedures for their preparation.  
This process represents a general one-pot method for the synthesis of novel 
oily amino-pyrrolidinyl phosphonates (17a-h) which have not reported before. 
In addition, they are thermally and air-stable compounds at room temperature, 
and are soluble in most organic solvents. Besides, this cyclization reaction is 
general for both aliphatic and aromatic primary amines as shown in Table 1. In 
addition, they are of potent biological activity precisely as antibiotics analogous 
to compounds 1-12 as shown in Table 2.  
Unlike primary amines, when secondary amines were used, no heterocycles 
were detected and only 2-amino-cyclobutenylphosphonates 16 were obtained.  
A suggested mechanism for this reaction can be attributed to initial addition 
of the amine on the carbon-carbon double bond to give a zwitterionic interme-
diate followed by proton transfer. Then, another hydroamination reaction took 
place on the double bond in the presence of excess amine to give the interme-
diate (20). After, nucleophilic attack of the nitrogen atom on C1 onto the carbon 
C-Cl by SN2 fashion, an aminopyrrolidinyl phosphonate (17) was produced 
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Table 1. Synthesis of pyrrolidinylphosphonates 17a-h.  
Entry Products Amine (3.1 equiv.) R Isolated Yielda, % (reaction conversion)b 
1 17a i-propylamine i-propyl 80 (>98) 
2 17b t-butylamine t-butyl 74 (>98) 
3 17c benzylamine benzyl 78 (>98) 
4 17d amylamine n-pentyl 75 (>98) 
5 17e n-butylamine n-butyl 77 (>98) 
6 17f phenylamine phenyl 76 (>98) 
7 17g n-heptylamine n-heptyl 75 (>98) 
8 17h 2-phenylethylamine phenylethyl 79 (>98) 
aAfter silica gel chromatography; b>98% as determined by GC/MS and 31P NMR. 
 
Table 2. Predicted biological activity of compounds 1-17. 
No. 
Experimental  
reported Activity,  
(Pa)* 




Inhibitor of the  
glycolytic enzyme  
enolase 2 
Stroke treatment (0.761); Neuroprotector (0.744); Acute neurologic disorders treatment (0.663);  
Antineoplastic (sarcoma) (0.646); Antinephrotoxic (0.587); Antiseborrheic (0.578) 
(15, 16, 21) 
2 Not reported 
Stroke treatment (0.979); Antiviral (0.897); Antiviral (HIV) (0.887) 
Antinephrotoxic (0.701); Bone formation stimulant (0.653) 
(29, 31) 
3 Not reported Antibiotic Glycopeptide-like (0.984); Stroke treatment (0.538) Antischistosomal (0.510) (21) 
4 Not reported 
Antiarthritic (0.963); Anti-inflammatory (0.942); Acute neurologic disorders treatment (0.765);  
Bone formation stimulant (0.615) Antinephrotoxic (0.608); Stroke treatment (0.567) 
Leukopoiesis stimulant (0.542); Bone diseases treatment (0.539) 
(30) 
5 Not reported 
Bone formation stimulant (0.813); Bone diseases treatment (0.803) Acute neurologic disorders  
treatment (0.650); Antinephrotoxic (0.604) Antiosteoporotic (0.560); Leukopoiesis stimulant (0.526) 
(31) 
6 Not reported 
Acute neurologic disorders treatment (0.834); Stroke treatment (0.583) Bone formation stimulant 
(0.574); Bone diseases treatment (0.536) Anesthetic general (0.517); Leukopoiesis stimulant (0.506) 
(31) 
7 Not reported Acetylesterase inhibitor (0.618); Anticonvulsant (0.533) (19, 20) 
8 Not reported Anticonvulsant (0.664); Acetylesterase inhibitor (0.637); Acute neurologic disorders treatment (0.513) (19, 20) 
9 Not reported Acetylesterase inhibitor (0.687); Myasthenia Gravis treatment (0.562) (19, 20) 
10 Not reported Cognition disorders treatment (0.765) (19, 20) 
11 Not reported Calcium regulator (0.548); Antihypertensive (0.503) (32) 
12 Not reported 
Acute neurologic disorders treatment (0.852); Stroke treatment (0.582) Bone diseases treatment 
(0.580); Bone formation stimulant (0.531) 
(33) 
17a Not reported Acetylesterase inhibitor (0.611); Insulinotropin antagonist (0.568) Present study 
17b Not reported Spasmolytic, urinary (0.954) Present study 
17c Not reported Acetylesterase inhibitor (0.572); Immunostimulant (0.522) Present study 
17d Not reported Acetylesterase inhibitor (0.618); Immunostimulant (0.544) Present study 
17e Not reported Acetylesterase inhibitor (0.618); Immunostimulant (0.544) Present study 
17f Not reported Purinergic P2Y2 antagonist (0.512) Present study 
17g Not reported No activities with Pa > 0.5 Present study 
17h Not reported General pump inhibitor (0.600) Present study 
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Scheme 3. Suggested mechanism for the synthesis of the compounds 17. 
 
This suggested mechanism is also supported by the fact that when secondary 
amines were used, no hetero cycles were detected and only  
2-amino-cyclobutenylphosphonates 16 were obtained. In addition, this reaction 
was restricted to 4-chloro-1-butynylphosphonate 15. When longer chloro alky-
nylphosphonates chains were used no heterocyclic structure was observed ap-
parently due to the proximity of the chloro substituted carbon to the conjugated 
system of the triple bond and the phosphonate group. After the synthesis of 
compounds (17a-h), their biological activity was screened utilizing the PASS 
program and were found to be of predicted pharmacological usefulness as listed 
in Table 2. 
3. Conclusion 
In conclusion, a novel aminopyrrolidinyl phosphonate class of compounds 
(17a-h) was smoothly obtained by addition of primary amines to  
4-chloro-1-butynylphosphonate in the absence of solvent or catalyst and rela-
tively in a satisfactory isolated yield. In addition, manifestations of biological ac-
tivities of the above compounds were observed using PASS program. This reac-
tion can be of interest for the related chemist’s community to apply this reaction 
to other functional groups instead of phosphonates and for the biologists to test 
their predicted biological activity.  
4. Experimental 
The 1H, 13C, and 31P NMR spectra were recorded from solutions in CDCl3 on a 
Varian Mercury 300 spectrometer at 300, 75.5, and 121.4 MHz, respectively; the 
chemical shifts were measured relative to TMS (1H, 13C) and H3PO4. The mass 
spectra (EI) were recorded on an HP G1800A GCD GC/MS instrument using a 
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Synthesis of Diethyl (4-chlorobut-1-yn-1-yl)phosphonate (15) 
Since the starting material 4-chlorobut-1-yne was not commercially available as 
usual, it was prepared in our lab [35].  
Synthesis of aminopyrrolidinyl phosphonates (17a-h) 
Typical procedure for the synthesis of diethyl  
(1-isopropyl-3-(isopropylamino)pyrrolidin-2-yl)phosphonate 17a. 
To diethyl (4-chlorobut-1-yn-1-yl)phosphonate (0.22 g, 1 mmol) was added 
(0.23 g, 3.5 mmol) of isopropylamine in a 10 mL round bottom flask. After stir-
ring at 25˚C for 12 h. the reaction mixture was washed with 0.1 N NaOH solu-
tion and the product was extracted with (2 × 20 mL CH2Cl2), dried over MgSO4, 
concentrated using a rotary evaporator and the oily product was separated on a 
silica gel column and was obtained in 80% isolated yield (10% methanol:90% 
dichloromethane), which was then analyzed by GC/MS, elemental analysis, and 
NMR spectroscopy. 
1H NMR (300 MHz, Chloroform d): δ 1.01 (d, 6H, JHH = 6.3 Hz), 1.11 (d, 6H, 
JHH = 6.3 Hz), 1.30 (t, 6H, JHH = 6.9 Hz), 1.65 - 2.30 (overlap, 3H), 2.65 - 70 (m, 
1H), 2.78 - 2.88 (overlap, 2H), 3.02 - 3.15 (m, 1H), 3.42 - 3.48 (m, 1H), 4.03 - 
4.12 (m, 4H); 31P NMR (121.4 MHZ, Chloroform d): δ 31.38; 13C NMR (75.5 
MHz, Chloroform d): 15.8 (d, 3JPC = 6.8), 15.8, 15.9, 32.0 (d, 1JPC = 126.7 Hz), 
44.4, 50.8 (d, 2JPC = 3.2 Hz), 53.1, 60.4 (d, 2JPC = 8.6 Hz), 62.1, 63.2; MS(EI):m/z 
(%) 306 (10.5), 305 (15.1), 287 (20.0), 235 (22.3), 168 (35.0), 152 (18.8), 123 
(30.0), 110 (41.3), 84 (100), 70 (56.7), 42 (19.9); Anal. Calcd. for C14H31N2O3P: C, 
54.88; H, 10.20; N, 9.14; P, 10.11. Found: C, 55.09; H, 10.37; N, 8.95; P, 9.97. 
Synthesis of diethyl  
(1-(tert-butyl)-3-(tert-butylamino)pyrrolidin-2-yl)phosphonate 17b. 
Identical to procedure 17a except adding t-butylamine and was obtained in 
74% isolated yield. 
1H NMR (300 MHz, Chloroform d): δ 1.09 (s, 9H), 1.11 (s, 9H), 1.31 (dt, 6H, 
JHH = 7.2 Hz, 3JHP = 2.1 Hz), 1.63 - 2.22 (overlap, 3H), 2.61 - 2.67 (overlap m, 
2H), 3.21 - 3.45 (m, 1H), 4.06 - 4.13 (m, 4H); 31P NMR (121.4 MHZ, Chloroform 
d): δ 30.38; 13C NMR (75.5 MHz, Chloroform d): 16.4 (d, 3JPC = 6.3), 28.8, 30.0, 
34.5 (d, 1JPC = 132.4 Hz), 39.7, 47.0, 50.6, 50.8 (d, 2JPC = 3.0 Hz), 60.4 (d, 2JPC = 8.6 
Hz); MS(EI): m/z (%) 334 (0.70), 319 (2.5), 289 (7.8), 277 (17.8), 244 (27.8), 220 
(70.5), 186 (51.1), 136 (100), 89 (55.1), 57 (67.8); Anal. Calcd. for C16H35N2O3P: 
C, 57.46; H, 10.55; N, 8.38; P, 9.26. Found: C, 58.18; H, 10.73; N, 8.21; P, 9.12. 
Synthesis of  
diethyl(1-benzyl-3-(benzylamino)pyrrolidin-2-yl)phosphonate 17c. 
Identical to procedure 17a except adding benzylamine and was obtained in 
78% isolated yield. 
1H NMR (300 MHz, Chloroform d): 1H NMR (300 MHz, Chloroform d): δ 
1.26 (dt, 6H, JHH = 6.9 Hz, 3JHP = 1.51 Hz), 1.69 - 2.18 (overlap, 3H), 2.64 - 283 
(m, 2H), 3.05 - 3.14 (m, 1H), 3.76 (s, 2H), 3.77 (s, 2H), 4.00 - 4.11 (m, 4H), 7.21 - 
7.33 (overlap, 10); 31P NMR (121.4 MHZ, Chloroform d): δ 30.98; 13C NMR (75.5 
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MHz, Chloroform d): 16.1 (d, 3JPC = 7.4), 30.5, 40.8, 47.5 (d, 1JPC = 126.7 Hz), 
45.5, 55.0, 60.2 (d, 2JPC = 4.0 Hz), 60.9 (d, 2JPC = 5.7 Hz), 127.7, 127.0, 128.2, 
141.5; MS(EI): m/z (%) 402 (3.1), 401 (4.7), 325 (15.4), 311(17.7), 295 (17.9), 266 
(30.4), 218 (44.9), 186 (22.3), 136 (60.1), 104 (33.6), 91 (100), 77 (55.8), 65 (18.8), 
54 (26.8); Anal. Calcd. for C22H31N2O3P: C, 65.65; H, 7.76; N, 6.96; P, 7.70. 
Found: C, 65.47; H, 7.64; N, 7.10; P, 7.81. 
Synthesis of diethyl  
(1-pentyl-3-(pentylamino)pyrrolidin-2-yl)phosphonate17d. 
Identical to procedure 17a except adding amylamine and was obtained in 75% 
isolated yield. 
1H NMR (300 MHz, Chloroform d): δ 0.89 (t, 3H, JHH = 5.7 Hz), 0.92 (t, 3H, 
JHH = 5.7 Hz), 1.31 (dt, 6H, JHH = 7.2 Hz, 3JHP = 2.1 Hz), 1.21 - 1.34 (overlap, 8H), 
1.40 - 1.51 (m, 2H), 1.53 - 1.70 (m, 2H), 1.80 - 2.21 (overlap, 3H), 2.55 - 2.80 
(overlap, 4H), 2.81 - 2.90 ((m, 1H), 3.00 - 3.05 (m, 1H), 3.06 - 3.15 (m, 1H), 4.06 
- 4.15 (m, 4H); 31P NMR (121.4 MHZ, Chloroform d): δ31.47; 13C NMR (75.5 
MHz, Chloroform d): 13.9, 14.1, 16.4 (d, 3JPC = 6.3), 22.4, 22.6, 26.4, 27.9, 29.2, 
29.5, 29.8, 30.1 (d, 1JPC = 137.4 Hz), 32.3, 46.5, 47.1, 48.9 (d, 2JPC = 3.0 Hz), 55.4, 
61.4 (d, 2JPC = 8.6 Hz); MS(EI): m/z (%) 362 (0.8), 319 (0.9), 279 (1.1), 264 (8.4), 
256 (2.0), 222 (15.0), 194 (42.9), 142 (28.1), 128 (100), 98 (28.8), 82 (14.3), 56 
(34.4), 43 (49.8), 29 (64.2); Anal. Calcd. for C18H39N2O3P: C, 59.64; H, 10.84; N, 
7.73; P, 8.54. Found: C, 59.77; H, 10.97; N, 7.60; P, 8.41. 
Synthesis of diethyl (1-butyl-3-(butylamino)pyrrolidin-2-yl)phosphonate 
17e. 
Identical to procedure 17a except adding butylamine and was obtained in 77% 
isolated yield. 
1H NMR (300 MHz, Chloroform d): δ 0.88 (t, 3H, JHH = 5.7 Hz), 0.96 (t, 3H, 
JHH = 5.7 Hz), 1.31 (dt, 6H, JHH = 7.2 Hz, 3JHP = 2.1 Hz), 1.35 - 1.48 (overlap, 
10H), 1.60 - 2.17 (overlap, 7H), 2.90 - 3.10 (m, 1H), 4.03 - 4.15 (m, 4H); 31P 
NMR (121.4 MHZ, Chloroform d): δ 31.85; 13C NMR (75.5 MHz, Chloroform 
d): 13.6, 14.0, 16.2 (d, 3JPC = 6.5), 23.0, 23.8, 28.3, 29.8, 30.3, 31.5 (d, 1JPC = 140.2 
Hz), 33.5, 48.1, 49.3 (d, 2JPC = 3.2 Hz), 50.0, 53.1, 62.0 (d, 2JPC = 8.4 Hz); 
MS(EI):m/z (%) 334 (0.9), 333 (1.0), 319 (16.8), 304 (40.2), 289 (17.6), 276 
(66.1), 219 (32.2), 189 (100), 135 (47.8), 89 (41.0), 57 (44.1); Anal. Calcd. for 
C16H35N2O3P: C, 57.46; H, 10.55; N, 8.38; P, 9.26. Found: C, 57.63; H, 10.70; N, 
8.19; P, 9.09. 
Synthesis of diethyl  
(1-phenyl-3-(phenylamino)pyrrolidin-2-yl)phosphonate 17f. 
Identical to procedure 17a except adding phenylamine and was obtained in 
76% isolated yield. 
1H NMR (300 MHz, Chloroform d): 1H NMR (300 MHz, Chloroform d): δ 
1.22 (dt, 6H, JHH = 6.9 Hz, 3JHP = 2.1 Hz), 1.73 - 2.20 (overlap, 3H), 2.58 - 2.80 
(m, 2H), 3.00 - 3.10 (m, 1H), 4.08 - 4.13 (m, 4H), 7.21 - 7.35 (overlap, 10); 31P 
NMR (121.4 MHZ, Chloroform d): δ 30.98; 13C NMR (75.5 MHz, Chloroform 
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d): 16.2 (d, 3JPC = 6.8), 29.8, 39.9, 48.8 (d, 1JPC = 132.1 Hz), 47.0, 61.0 (d, 2JPC = 2.8 
Hz), 62.5 (d, 2JPC = 5.7 Hz), 127.9, 128.8, 129.2, 141.0; MS(EI): m/z (%) 374 (0.7), 
373 (1.2), 297 (30.0), 255 (20.1), 220 (100), 189 (35.9), 137 (28.7), 89 (18.7), 77 
(67.9), 65 (30.0); Anal. Calcd. for C20H27N2O3P: C, 64.16; H, 7.27; N, 7.48; P, 8.27. 
Found: C, 63.98; H, 7.13; N, 7.60; P, 8.41. 
Synthesis of diethyl  
(1-heptyl-3-(heptylamino)pyrrolidin-2-yl)phosphonate 17g. 
Identical to procedure 17a except adding heptylamine and was obtained in 
75% isolated yield. 
1H NMR (300 MHz, Chloroform d): δ 0.88 (t, 3H, JHH = 5.7 Hz), 0.96 (t, 3H, 
JHH = 5.7 Hz), 1.28 (dt, 6H, JHH = 7.2 Hz, 3JHP = 2.1 Hz), 1.30 - 1.60 (overlap, 
16H), 1.74 - 2.18 (overlap, 13H), 2.93 - 3.20 (m, 1H), 4.04 - 4.10 (m, 4H); 31P 
NMR (121.4 MHZ, Chloroform d): δ 32.25; 13C NMR (75.5 MHz, Chloroform 
d): 13.6, 14.0, 16.0 (d, 3JPC = 6.1), 22.2, 22.7, 26.9, 27.0, 27.9, 28.2, 28.8, 29.0, 29.4, 
29.8, 31.0 (d, 1JPC = 135.8 Hz), 33.3, 45.2, 46.9 (d, 2JPC = 3.2 Hz), 49.0, 53.0, 60.8 
(d, 2JPC = 8.6 Hz); MS(EI): m/z (%) 418 (0.7), 417 (0.9), 412 (11.2), 396 (14.8), 
345 (20.7), 289 (49.6), 235 (33.8), 189 (100), 135 (60.3), 87 (57.7), 43 (45.8); Anal. 
Calcd. for C22H47N2O3P: C, 63.12; H, 11.32; N, 6.69; P, 7.40. Found: C, 62.91; H, 
11.17; N, 6.81; P, 7.56. 
Synthesis of diethyl  
(1-phenethyl-3-(phenethylamino)pyrrolidin-2-yl)phosphonate17h. 
Identical to procedure 17a except adding phenylethylamine and was obtained 
in 79% isolated yield. 
1H NMR (300 MHz, Chloroform d): 1H NMR (300 MHz, Chloroform d): δ 
1.24 (dt, 6H, JHH = 6.9 Hz, 3JHP = 1.67 Hz), 1.58 - 2.18 (overlap, 3H), 2.14 - 2.85 
(overlap, 7H), 4.04 - 4.15 (m, 4H), 7.17 - 7.31 (overlap, 10); 31P NMR (121.4 
MHZ, Chloroform d): δ 31.78; 13C NMR (75.5 MHz, Chloroform d): 16.2 (d, 3JPC 
= 7.2), 31.3, 32.8, 41.5, 49.5 (d, 1JPC = 132.9 Hz), 48.2, 55.6, 57.9, 61.0 (d, 2JPC = 4.2 
Hz), 60.9 (d, 2JPC = 5.7 Hz), 127.7, 127.0, 128.2, 141.5; MS(EI): m/z (%) 430 (0.7), 
429 (0.8), 353 (18.9), 325 (32.1), 276 (100), 234 (22.8), 188 (45.9), 135 (57.7), 105 
(77.8), 77 (46.8), 69 (66.7); Anal. Calcd. for C24H35N2O3P: C, 66.96; H, 8.19; N, 
6.51; P, 7.19. Found: C, 67.08; H, 8.31; N, 6.37; P, 7.06. 
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